News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

28 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita

28 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces CHF 15 Million Private Placement

26 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil

23 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting

22 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

20 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial

13 July 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

29 June 2021
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority

21 June 2021
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

16 June 2021

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

MC Services AG
Anne Hennecke
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +49 (0) 211-529-252-22

Latest News

Corporate News

Archive

Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita

Relief Therapeutics Announces CHF 15 Million Private Placement

Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil

Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting

Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial

Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events